Company Of The Day: Merck
What?
Merck (NYSE:MRK) and AstraZenica’s cancer drug Lynparza has been approved by the U.S. FDA to treat patients with early-stage breast cancer with certain mutations.
So What?
Relevant Articles
- After A 30% Fall In A Year Is Pfizer Stock A Better Pick Over Merck?
- At $100 Does Merck Stock Have Room For Growth?
- Should You Pick Merck Stock Over Coca-Cola?
- Should You Buy Merck Stock After An Upbeat Q2?
- How Has Merck Stock Performed During The 2022-23 Inflation Shock?
- Is Merck Stock A Better Pick Over ABBV?
Merck’s alliance revenue from Lynparza stood at about $989 million in 2021, growing 36% year-over-year, making it one of the company’s fastest-growing drugs. It’s likely that the new approval could increase sales further.
See Our Complete Analysis For Merck
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since the end of 2016.
| Returns | Mar 2022 MTD [1] |
2022 YTD [1] |
2017-22 Total [2] |
| MRK Return | 2% | 2% | 33% |
| S&P 500 Return | -4% | -12% | 88% |
| Trefis MS Portfolio Return | -4% | -14% | 238% |
[1] Month-to-date and year-to-date as of 3/14/2022
[2] Cumulative total returns since the end of 2016
Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates